cisplatin,pembrolizumab,gemcitabine,pemetrexed
merck
['nsclc', 'pembro', 'sclc']
the 24-month efs rate was 62.4% with pembrolizumab plus chemotherapy and adjuvant pembrolizumab compared with 40.6% for placebo plus chemotherapy (hr, 0.58; 95% ci, 0.46-0.72; p &lt; .00001). #nsclc #asco23 | 
Home of the journal ONCOLOGY®, CancerNetwork® offers different perspectives on oncology/hematology through review articles, news, podcasts, blogs, and more.